Table 1.

Patient characteristics, therapy, and response.

Patient	Age/Sex	Body weight (kg)	Diagnosis	Sites of disease	MAGE-A IHC	Prior therapy	Cells (× 109)	IL-2 doses	Response	Neurological toxicity
1	59/M	102.6	Melanoma	lung	3+, >80%	Surgery, IL-2, NY ESO-1 TCR, Chemo, XRT	28	6	CR (15+)	none
2	38/F	110	Melanoma	R axilla, L periadrenal, R breast, retrocaval, brain	2+, >70%	Surgery, IFN, IL-2, MART-1 TCR, Zanolimumab, TIL, Chemo, XRT	30	5	NR	none
3	56/F	59.5	Melanoma	Subcu, intraabd, R axilla, omentum	3+, >90%	Surgery, IL-2, TIL-IL12, Chemo	30	7	PR (4)	none
4	21/F	74.2	Synovial sarcoma	lung	3+, >90%	Surgery, XRT, Chemo, NY ESO-1 TCR, ALVAC, IL2	41	1	PR (5)	none
5	54/M	94.8	Melanoma	lung, subcu, mesenteric nodes, brain, R axilla, spleen, paratracheal	2–3+, >70%	Surgery, IFN, XRT, IL2, Zanolimumab	79	5	PR(4)	Seizures, coma, TRM
6	44/M	64.6	Melanoma	Right thigh, R iliac nodes	3+, >95%	Surgery, Chemo, GM-CSF, TIL, IL-2	53	4	NR	none
7	62/M	82.7	Melanoma	lymph node, rib	3+, >90%	Surgery, INF, IL2	62	6	PR (12+)	Seizure, MS
8	71/F	43.5	Esophageal cancer	Mediastinal; bilat lung	3+, >90%	Surgery, XRT, Chemo	61	1	NR	Coma, TRM
9	62/F	99.2	Melanoma	Liver, subcu and L axilla, intra-abd, neck/cervical, vertebral	3+, >50%	Surgery, IFN, IL-2, NY ESO-1 TCR, Chemo, ALVAC	30	0	NR	TIA

Abbreviations: IL-2, interleukin-2; IFN, interferon; Chemo, chemotherapy; TCR, T cell receptor; ALVAC, modified canary pox virus vaccine; GM-CSF, granulocyte-macrophage colony-stimulating factor; M, male; ln, lymph node; XRT, radiation; F, female; subc, subcutaneous; L, left; R, right; bilat, bilateral; abd, abdominal; MS, mental status; TRM, treatment related mortality; IHC, immunohistochemistry; IL12, interleukin-12; TIA, transient ischemic attack; CR, complete response; PR, partial response; NR, no response.